PP
TEVA icon

Paloma Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Paloma Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-14,643
Closed -$238K – 1661
2024
Q2 		$238K Buy
+14,643
New +$226K 0.01% 959
2021
Q2 		– Sell
-12,800
Closed -$148K – 2262
2021
Q1 		$148K Buy
+12,800
New +$147K ﹤0.01% 1853
2020
Q4 		– Sell
-195,000
Closed -$1.76M – 2205
2020
Q3 		$1.76M Buy
+195,000
New +$2.06M 0.04% 437
2019
Q4 		– Sell
-19,623
Closed -$135K – 2503
2019
Q3 		$135K Buy
+19,623
New +$150K ﹤0.01% 1810
2017
Q4 		– Sell
-12,663
Closed -$223K – 2285
2017
Q3 		$223K Buy
+12,663
New +$285K ﹤0.01% 1938
2017
Q1 		– Sell
-22,038
Closed -$798K – 2233
2016
Q4 		$798K Buy
22,038
+8,003
+57% +$320K 0.01% 1285
2016
Q3 		$646K Buy
+14,035
New +$732K 0.01% 1275
2016
Q2 		– Sell
-23,163
Closed -$1.24M – 2338
2016
Q1 		$1.24M Buy
23,163
+14,739
+175% +$865K 0.02% 747
2015
Q4 		$553K Sell
8,424
-6,111
-42% -$378K 0.01% 980
2015
Q3 		$821K Buy
14,535
+7,998
+122% +$519K 0.02% 759
2015
Q2 		$386K Buy
+6,537
New +$403K 0.01% 1206
2015
Q1 		– Sell
-11,600
Closed -$667K – 1421
2014
Q4 		$667K Sell
11,600
-29,300
-72% -$1.63M 0.03% 565
2014
Q3 		$2.2M Buy
40,900
+5,550
+16% +$294K 0.1% 200
2014
Q2 		$1.85M Hold
35,350
– – 0.08% 245
2014
Q1 		$1.87M Buy
35,350
+13,190
+60% +$610K 0.12% 157
2013
Q4 		$888K Buy
22,160
+7,110
+47% +$280K 0.04% 419
2013
Q3 		$569K Sell
15,050
-5,292
-26% -$206K 0.02% 465
2013
Q2 		$797K Buy
+20,342
New +$792K 0.04% 317

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Paloma Partners's TEVA Position: Q3 2024 in Review

Paloma Partners sold out of Teva Pharmaceuticals (TEVA) in Q3 2024, closing a stake of 14,643 shares — an estimated $238K sold.

Paloma Partners first reported a position in TEVA in Q2 2013 and held it in 18 quarters. The position peaked at $2.2M in Q3 2014. 542 funds tracked by Wall St. Rank hold TEVA as of Q3 2024.

  • Paloma Partners reported no remaining Teva Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Paloma Partners sold 14,643 Teva Pharmaceuticals shares in Q3 2024, an estimated $238K.
  • Paloma Partners first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 18 quarters.
  • Paloma Partners's Teva Pharmaceuticals position peaked at $2.2M in Q3 2014.
  • 542 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2024.

Based on Paloma Partners's 13F filing for Q3 2024, filed 14 Nov 2024.